Sangamo BioSciences | SGMO - Interest Expense On Debt


Sangamo BioSciences reported 97.56M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
Bayer EUR 675M 87M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Cipla INR 131.3M 9M Mar/2026
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Grifols EUR 156.07M 31.46M Sep/2025
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Merck USD 479M 67M Mar/2026
Novartis USD 343M 39M Mar/2026
Omeros USD 4.05M 5.16M Sep/2024
Pfizer USD 671M 40M Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025